Compare NOMD & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMD | NBTX |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | 2015 | 2018 |
| Metric | NOMD | NBTX |
|---|---|---|
| Price | $11.74 | $30.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $13.82 | ★ $54.24 |
| AVG Volume (30 Days) | ★ 1.2M | 126.0K |
| Earning Date | 11-04-2026 | 09-24-2026 |
| Dividend Yield | ★ 5.66% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.31 | $50.69 |
| P/E Ratio | $8.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.99 | $19.14 |
| 52 Week High | $13.08 | $57.14 |
| Indicator | NOMD | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.11 | 52.98 |
| Support Level | $11.61 | $30.15 |
| Resistance Level | $12.18 | $35.17 |
| Average True Range (ATR) | 0.28 | 1.97 |
| MACD | -0.01 | 0.47 |
| Stochastic Oscillator | 13.07 | 67.29 |
Nomad Foods Ltd is a packaged foods company that is involved in the business of manufacturing and distributing branded frozen foods in Western Europe. The company manufactures and markets frozen food products such as fish, vegetables, poultry, Ice Cream, and ready meals like pizza. It sells its products through large grocery retailers under the brand Birds Eye in the United Kingdom and Ireland, Findus in Italy, France, Spain, and Iglo in Germany and other continental markets. The company operates through a single segment being Frozen. The majority of the revenue is generated from the United Kingdom.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.